{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Waiting for the Antidote: The Journey of Idarucizumab as a Potential Specific Reversal Agent for Dabigatran (Pradaxa)

Purpose of Activity

To provide information on anticoagulants and the development of idarucizumab as an antidote for dabigatran.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Recognize features of various anticoagulants.
  2. Examine data from trials of idarucizumab.
Price: $21.95

Credits:

  • ANCC 2.0 CH / 1.5 APH
  • DC - BON 2.0 CH
  • FL - BON 2.0 CH

Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
--------------------------------------------------
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #50-1223. Your certificate is valid in all states.

Awarded Advanced Pharmacology Hours





Test Code: CNS0915
Published: Sep/Oct 2015
Expires: 9/6/2019
Passing Score: 13/18 (72%)
Authors: Patricia Anne O'Malley, PhD, RN, CNS